Eli Lilly and Company (NYSE:LLY) Now Covered by Analysts at Sanford C. Bernstein

Sanford C. Bernstein started coverage on shares of Eli Lilly and Company (NYSE:LLY) in a research note released on Thursday morning, Marketbeat reports. The firm issued an outperform rating and a $1,100.00 price objective on the stock.

Several other equities analysts also recently issued reports on the stock. Bank of America upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Jefferies Financial Group increased their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Citigroup began coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They set a “buy” rating and a $1,060.00 price target on the stock. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,002.24.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $917.97 on Thursday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company has a market capitalization of $872.44 billion, a price-to-earnings ratio of 135.19, a PEG ratio of 2.79 and a beta of 0.42. The company’s 50 day simple moving average is $921.21 and its 200 day simple moving average is $858.60. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, sell-side analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LLY. Banque Cantonale Vaudoise grew its holdings in Eli Lilly and Company by 9.9% during the 1st quarter. Banque Cantonale Vaudoise now owns 26,503 shares of the company’s stock worth $20,617,000 after acquiring an additional 2,383 shares in the last quarter. Conrad Siegel Investment Advisors Inc. bought a new position in shares of Eli Lilly and Company in the 1st quarter worth about $231,000. Wedmont Private Capital lifted its position in shares of Eli Lilly and Company by 5.6% in the 1st quarter. Wedmont Private Capital now owns 11,825 shares of the company’s stock worth $8,955,000 after buying an additional 627 shares during the last quarter. Grandview Asset Management LLC lifted its position in shares of Eli Lilly and Company by 42.4% in the 1st quarter. Grandview Asset Management LLC now owns 763 shares of the company’s stock worth $593,000 after buying an additional 227 shares during the last quarter. Finally, Lantz Financial LLC lifted its position in shares of Eli Lilly and Company by 1.6% in the 1st quarter. Lantz Financial LLC now owns 1,220 shares of the company’s stock worth $949,000 after buying an additional 19 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.